Merck's positive Phase III tafluprost results may bode well for US approval
This article was originally published in Scrip
Executive Summary
Patients with open-angle glaucoma or ocular hypertension who received once-daily dosages an investigational ophthalmic drug from Merck, known as tafluprost, a preservative-free (PF) prostaglandin analogue, experienced a substantial reduction in intraocular pressure (IOP) comparable to those who received twice-daily dosages of PF timolol maleate, new Phase III results have demonstrated.